[Pilot trial of vaccines based on autologous dendritic cells loaded in vitro with tumor antigens in the treatment of cancer of the urinary bladder].
Dendritic cells (DC) are most potent antigen-presenting cells controlling immune response by means of interaction with lymphocytes. Antitumor vaccines based on DC are produced by means of the patient's DC culturing and loading with tumor antigens in vitro. This provides mature antigen-loaded DC able to activate immune response. Pilot results of the trial of the efficacy of the above antitumor vaccine in the treatment of bladder cancer demonstrate perspectives of the vaccines as an adjuvant in mono- and/or combined treatment of bladder cancer.